(24/7 MARKET NEWS) – this morning’s 15 minutes after the opening bell snap shot.
Palisade Bio, Inc. (PALI:NASDAQ) entered into a licensing agreement with Giiant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform focused on therapies for the multi-billion dollar IBD market. Palisade is trading at $1.55, up $0.86 (+124.67%), on 37.3M shares. We covered it this morning at $1.05, up $0.3603 (+52.24%), on 6.70M premarket shares traded and stated that it may try to refill the gap to nearly $2.
Trevena, Inc. (TRVN: NASDAQ) received a $15 million tranche under its non-dilutive R-Bridge ex-US royalty-based financing, which was triggered by the first commercial sale of OLINVYK in China by Jiangsu Nhwa, the Company’s licensee in China. Trevena is trading at $1.03, up $0.13 (+14.42%), on 18.06M shares traded.
Marin Software (MRIN:NASDAQ) is running after announcing HubSpot integration and is trading at $0.53, up $0.10 (+23.00%), on 8.81M shares.
Roku, Inc (ROKU:NASDAQ) is trading higher after announcing new cost cutting initiatives; it’s trading at $93.15, up $9.42 (+11.25%(, on 7.07M shares.
Foxo Tech (FOXO:NASDAQ) is trading at $0.23, up $0.09 (+59.16%), on 37.6M shares.
NeuBase Therapeutics (NBSE:NASDAQ) is trading at $1.24, up $0.09 (+7.77%), on 8.01M shares.
System1, Inc. (SST:NYSE) received a non-binding indication of interest from Just Develop It Limited regarding the possible acquisition of Total Security Limited for $240 million in cash, the assumption of certain potential earnout payments in respect of Total Security and the delivery of approximately 29 million System1 shares held by Just Develop It and related persons. SST System1 is at $1.99, up $0.15 (+8.15%), on 2.95M shares.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.